BIOMAT Database Logo BIOMAT Database Logo

A randomized study of the effects of food on the pharmacokinetics of once-daily extended-release hydromorphone in healthy volunteers. 2011

Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
Johnson & Johnson Pharmaceutical Research & Development, 1125 Trenton-Harbourton Rd, Titusville, NJ 08560, USA. tmoore17@its.jnj.com

This randomized, open-label, crossover study investigated the influence of food on the pharmacokinetics of extended-release hydromorphone in 30 healthy volunteers. Participants received extended-release hydromorphone 16 mg in the fasted state and immediately after a high-fat breakfast. In addition, the pharmacokinetics of a 16-mg dose of extended-release hydromorphone and a 16-mg daily dose (4 mg qid) of immediate-release hydromorphone in the fasted state were compared. Treatments were separated by washout periods of 7 to 14 days. Naltrexone was given throughout each treatment period to block the opioid effects of hydromorphone. The 90% confidence intervals (CIs) of the ratios of geometric means for maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve (AUC) for extended-release hydromorphone in the fed and fasted states were within the bioequivalence criteria range of 80% to 125%. In the fasted state, the 90% CIs of the ratios of AUC geometric means for extended-release hydromorphone and immediate-release hydromorphone were also within the bioequivalence range. Both hydromorphone treatments were well tolerated. This study shows that the bioavailability of extended-release hydromorphone is not affected by food and that the bioavailability of extended-release hydromorphone under fasting conditions is comparable with that of the immediate-release formulation when administered at the same total daily dose.

UI MeSH Term Description Entries
D008297 Male Males
D009271 Naltrexone Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Antaxone,Celupan,EN-1639A,Nalorex,Naltrexone Hydrochloride,Nemexin,ReVia,Trexan,EN 1639A,EN1639A
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004091 Hydromorphone An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine. Dihydromorphinone,Hydromorphon,Dilaudid,Hydromorphone Hydrochloride,Laudacon,Palladone
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
June 2011, Clinical therapeutics,
Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules.
May 2005, Journal of clinical pharmacology,
Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
November 2009, Clinical therapeutics,
Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
Pharmacokinetics of a New, Once-Daily, Sustained-release Pregabalin Tablet in Healthy Male Volunteers.
August 2021, Clinical therapeutics,
Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study.
January 2009, Clinical drug investigation,
Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies.
December 2019, Neurology and therapy,
Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets.
August 2019, CNS drugs,
Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects.
December 2011, International journal of clinical pharmacology and therapeutics,
Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
Dose equivalence of immediate-release hydromorphone and once-daily osmotic-controlled extended-release hydromorphone: a randomized, double-blind trial incorporating a measure of assay sensitivity.
April 2012, The journal of pain,
Kenneth Todd Moore, and Dominique St-Fleur, and Nadia Cardillo Marricco, and Jay Ariyawansa, and Véronique Pagé, and Jayalakshmi Natarajan, and Gaetano Morelli, and Ute Richarz
A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers.
December 2014, Transplant international : official journal of the European Society for Organ Transplantation,
Copied contents to your clipboard!